The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies

Gaetano Bertino, Shirin Demma, Annalisa Ardiri, Maria Proiti, Alessandra Mangia, Salvatore Gruttadauria, Adriana Toro, Isidoro Di Carlo, Giulia Malaguarnera, Nicoletta Bertino, Mariano Malaguarnera, Michele Malaguarnera

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background. Hepatocellular carcinoma is a major health problem worldwide and the third most common cause of cancer-related death. HCC treatment decisions are complex and dependent upon tumor staging. Several molecular targeted agents have been evaluated in clinical trials in advanced HCC. Despite of only modest objective response rates according to the Response Evaluation Criteria in Solid Tumors, several studies showed encouraging results in terms of prolongation of the time to progression, disease stabilization, and survival. Cellular immunotherapy would improve the immune state and has potential in enhancing the therapeutic outcome for HCC patients. Materials and Methods. A search of the literature was made using cancer literature, the PubMed, Scopus, and Web of Science (WOS) database for the following keywords: "hepatocellular carcinoma," "molecular hepatocarcinogenesis," "targeted therapy," "molecular immunological targets," "tumour-associated antigens," "Tregs," "MDSCs," "immunotherapy." Discussion and Conclusion. Treatment strategies combining blockade of immunoregulatory cell types such as Tregs and MDSCs and of inhibitory receptors, with vaccine-induced activation of TAA-specific T cells, may be necessary to achieve the most effective therapeutic antitumour activity in HCC. In the future, new therapeutic options will be represented by a blend of immunotherapy-like vaccines and T-cell modulators, supplemented by molecularly targeted inhibitors of tumor signaling pathways.

Original languageEnglish
Article number731469
JournalBioMed Research International
Volume2015
DOIs
Publication statusPublished - 2015

Fingerprint

Immune system
Tumors
Hepatocellular Carcinoma
Immune System
T-cells
Immunotherapy
Vaccines
Molecular Targeted Therapy
T-Lymphocytes
Therapeutics
Medical problems
Neoplasms
Modulators
Neoplasm Staging
Neoplasm Antigens
PubMed
Stabilization
Chemical activation
Disease Progression
Antigens

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Cite this

The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies. / Bertino, Gaetano; Demma, Shirin; Ardiri, Annalisa; Proiti, Maria; Mangia, Alessandra; Gruttadauria, Salvatore; Toro, Adriana; Di Carlo, Isidoro; Malaguarnera, Giulia; Bertino, Nicoletta; Malaguarnera, Mariano; Malaguarnera, Michele.

In: BioMed Research International, Vol. 2015, 731469, 2015.

Research output: Contribution to journalArticle

Bertino, G, Demma, S, Ardiri, A, Proiti, M, Mangia, A, Gruttadauria, S, Toro, A, Di Carlo, I, Malaguarnera, G, Bertino, N, Malaguarnera, M & Malaguarnera, M 2015, 'The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies', BioMed Research International, vol. 2015, 731469. https://doi.org/10.1155/2015/731469
Bertino, Gaetano ; Demma, Shirin ; Ardiri, Annalisa ; Proiti, Maria ; Mangia, Alessandra ; Gruttadauria, Salvatore ; Toro, Adriana ; Di Carlo, Isidoro ; Malaguarnera, Giulia ; Bertino, Nicoletta ; Malaguarnera, Mariano ; Malaguarnera, Michele. / The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies. In: BioMed Research International. 2015 ; Vol. 2015.
@article{7ec09ae5fbcb4344884c92adc3f59fe9,
title = "The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies",
abstract = "Background. Hepatocellular carcinoma is a major health problem worldwide and the third most common cause of cancer-related death. HCC treatment decisions are complex and dependent upon tumor staging. Several molecular targeted agents have been evaluated in clinical trials in advanced HCC. Despite of only modest objective response rates according to the Response Evaluation Criteria in Solid Tumors, several studies showed encouraging results in terms of prolongation of the time to progression, disease stabilization, and survival. Cellular immunotherapy would improve the immune state and has potential in enhancing the therapeutic outcome for HCC patients. Materials and Methods. A search of the literature was made using cancer literature, the PubMed, Scopus, and Web of Science (WOS) database for the following keywords: {"}hepatocellular carcinoma,{"} {"}molecular hepatocarcinogenesis,{"} {"}targeted therapy,{"} {"}molecular immunological targets,{"} {"}tumour-associated antigens,{"} {"}Tregs,{"} {"}MDSCs,{"} {"}immunotherapy.{"} Discussion and Conclusion. Treatment strategies combining blockade of immunoregulatory cell types such as Tregs and MDSCs and of inhibitory receptors, with vaccine-induced activation of TAA-specific T cells, may be necessary to achieve the most effective therapeutic antitumour activity in HCC. In the future, new therapeutic options will be represented by a blend of immunotherapy-like vaccines and T-cell modulators, supplemented by molecularly targeted inhibitors of tumor signaling pathways.",
author = "Gaetano Bertino and Shirin Demma and Annalisa Ardiri and Maria Proiti and Alessandra Mangia and Salvatore Gruttadauria and Adriana Toro and {Di Carlo}, Isidoro and Giulia Malaguarnera and Nicoletta Bertino and Mariano Malaguarnera and Michele Malaguarnera",
year = "2015",
doi = "10.1155/2015/731469",
language = "English",
volume = "2015",
journal = "BioMed Research International",
issn = "2314-6133",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies

AU - Bertino, Gaetano

AU - Demma, Shirin

AU - Ardiri, Annalisa

AU - Proiti, Maria

AU - Mangia, Alessandra

AU - Gruttadauria, Salvatore

AU - Toro, Adriana

AU - Di Carlo, Isidoro

AU - Malaguarnera, Giulia

AU - Bertino, Nicoletta

AU - Malaguarnera, Mariano

AU - Malaguarnera, Michele

PY - 2015

Y1 - 2015

N2 - Background. Hepatocellular carcinoma is a major health problem worldwide and the third most common cause of cancer-related death. HCC treatment decisions are complex and dependent upon tumor staging. Several molecular targeted agents have been evaluated in clinical trials in advanced HCC. Despite of only modest objective response rates according to the Response Evaluation Criteria in Solid Tumors, several studies showed encouraging results in terms of prolongation of the time to progression, disease stabilization, and survival. Cellular immunotherapy would improve the immune state and has potential in enhancing the therapeutic outcome for HCC patients. Materials and Methods. A search of the literature was made using cancer literature, the PubMed, Scopus, and Web of Science (WOS) database for the following keywords: "hepatocellular carcinoma," "molecular hepatocarcinogenesis," "targeted therapy," "molecular immunological targets," "tumour-associated antigens," "Tregs," "MDSCs," "immunotherapy." Discussion and Conclusion. Treatment strategies combining blockade of immunoregulatory cell types such as Tregs and MDSCs and of inhibitory receptors, with vaccine-induced activation of TAA-specific T cells, may be necessary to achieve the most effective therapeutic antitumour activity in HCC. In the future, new therapeutic options will be represented by a blend of immunotherapy-like vaccines and T-cell modulators, supplemented by molecularly targeted inhibitors of tumor signaling pathways.

AB - Background. Hepatocellular carcinoma is a major health problem worldwide and the third most common cause of cancer-related death. HCC treatment decisions are complex and dependent upon tumor staging. Several molecular targeted agents have been evaluated in clinical trials in advanced HCC. Despite of only modest objective response rates according to the Response Evaluation Criteria in Solid Tumors, several studies showed encouraging results in terms of prolongation of the time to progression, disease stabilization, and survival. Cellular immunotherapy would improve the immune state and has potential in enhancing the therapeutic outcome for HCC patients. Materials and Methods. A search of the literature was made using cancer literature, the PubMed, Scopus, and Web of Science (WOS) database for the following keywords: "hepatocellular carcinoma," "molecular hepatocarcinogenesis," "targeted therapy," "molecular immunological targets," "tumour-associated antigens," "Tregs," "MDSCs," "immunotherapy." Discussion and Conclusion. Treatment strategies combining blockade of immunoregulatory cell types such as Tregs and MDSCs and of inhibitory receptors, with vaccine-induced activation of TAA-specific T cells, may be necessary to achieve the most effective therapeutic antitumour activity in HCC. In the future, new therapeutic options will be represented by a blend of immunotherapy-like vaccines and T-cell modulators, supplemented by molecularly targeted inhibitors of tumor signaling pathways.

UR - http://www.scopus.com/inward/record.url?scp=84928116687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928116687&partnerID=8YFLogxK

U2 - 10.1155/2015/731469

DO - 10.1155/2015/731469

M3 - Article

C2 - 25893197

AN - SCOPUS:84928116687

VL - 2015

JO - BioMed Research International

JF - BioMed Research International

SN - 2314-6133

M1 - 731469

ER -